T2DM合并NAFLD患者血清内脂素、体成分和ACR变化及其与发生大血管并发症的关系研究*

doi:10.3969/j.issn.1672-5069.2026.01.015

Abstract

Abstract: Objective The aim of this study was to investigate serum visfatin, body composition and urinary albumin to creatinine ratio (ACR) changes in patients with type 2 diabetes mellitus (T2DM) and concomitant nonalcoholic fatty liver disease (NAFLD) and their relationship with the occurrence of macrovascular complications. Methods 237 patients with T2DM, of which including T2DM with concomitant NAFLD in 122 cases, were enrolled in our hospital between January 2022 and January 2025. Serum visfatin level was assayed by ELISA. Abdominal fat, visceral fat and visceral fat area were detected and calculated by body composition analyzer. Microalbuminuria and creatinine levels were routinely determined and ACR was calculated. Binary Logistic regression model was applied to analyze the risk factors of macrovascular disorders in patients with T2DM and NAFLD. Results Blood pressure, body mass index (BMI)and waist circumference (WC) in patients with T2DM and NAFLD were much greater or higher than in patients T2DM(P<0.05); serum visfatin, abdominal fat, visceral fat, visceral fat area and ACR in patients with T2DM and NAFLD were(35.8±8.6)ng/mL, (8.9±2.3)kg, (2.9±0.8)kg, (91.8±20.6)cm² and (29.6±6.8)mg/g, all significantly higher than [(20.7±5.4)ng/mL, (7.1±1.4)kg, (2.2±0.7)kg, (64.5±12.4)cm² and (21.2±5.1)mg/g, respectively, P<0.05] in patients with T2DM; of 122 patients with T2DM and NAFLD, macrovascular disorders was found in 31 cases (25.4%); BMI, WC, serum visfatin, abdominal fat and ACR in patients with macrovascular disorders were all significnalty higher than in those without(P<0.05); binary Logistic regression analysis showed that BMI(OR=3.108), serum visfatin (OR=4.187) and ACR (OR=4.362) were all the independent risk factors for occurrence of macrovascular disorders in patients with T2DM and NAFLD (P＜0.05). Conclusion Condition of patients with T2DM and NAFLD could be complicated by macrovascular disorders, and surveillance of serum visfatin, body composition and ACR might provide a hint for it.

Key words: Nonalcoholic fatty liver disease, Type 2 diabetes mellitus, Visfatin, Body composition, Urinary albumin to creatinine ratio, Macrovascular disorders

Li Lei, Wang Huanhuan, Song Lige, et al. Serum visfatin, body composition and ACR changes in patients with type 2 diabetes mellitus and concomitant nonalcoholic fatty liver disease and their relationship with the occurrence of macrovascular complications[J]. Journal of Practical Hepatology, 2026, 29(1): 57-60.

References

[1] 秦浩,方春华,何競,等. 六种无创评分诊断2型糖尿病合并代谢相关脂肪性肝病患者效能比较. 实用肝脏病杂志,2025,28(3):366-369.
[2] 王文川,梁阔鹏,何蕊玲,等. 社区2型糖尿病合并NAFLD患病流行率调查. 实用肝脏病杂志,2024,27(1):40-43.
[3] 倪文婧,李婕,南月敏.非酒精性脂肪性肝病合并糖尿病的综合管理:2024年美国糖尿病学会指南解读.中华肝脏病杂志,2024,32(6):504-507.
[4] Fang J, Yu CH, Li XJ,et al. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications. Front Cell Infect Microbiol, 2022,12:997018.
[5] Tavaglione F, Amangurbanova M, Yang AH, et al. Head-to-head comparison between phosphatidylethanol versus indirect alcohol biomarkers for diagnosis of METALD versus MASLD: a prospective study. Aliment Pharmacol Ther, 2025,61(6):1043-1054.
[6] 中华人民共和国卫生部. 中华人民共和国卫生行业标准T2DM筛查和诊断. 实用防盲技术,2012,7(4):180-184.
[7] 中华医学会肝病学分会.代谢相关(非酒精性)脂肪性肝病防治指南(2024年版).实用肝脏病杂志,2024,27(4): 494-510.
[8] Zhao H, Shu L, Huang W,et al. Difference analysis of related factors in macrovascular and microvascular complications in Chinese patients with type 2 diabetes mellitus: a case-control study protocol. Diabetes Metab Syndr Obes, 2019,12:2193-2200.
[9] 郑慧慧,王玉蓉,宰国田. 非酒精性脂肪性肝病合并颈动脉粥样硬化斑块患者血清IL-17、IFN-γ和IL-6变化及其临床意义探讨. 实用肝脏病杂志,2025,28(1):56-59.
[10] Caussy C, Aubin A, Loomba R. Therelationship between type 2 diabetes, NAFLD, and cardiovascular risk. Curr Diab Rep, 2021,21(5):15.
[11] Kumar A, Sundaram K, Teng Y,et al. Ginger nanoparticles mediated induction of Foxa2 prevents high-fat diet-induced insulin resistance. Theranostics, 2022,12(3):1388-1403.
[12] Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol, 2021,17(8):484-495.
[13] Sakurai Y, Kubota N, Yamauchi T,et al. Role of insulin resistance in MAFLD. Int J Mol Sci, 2021,22(8):4156.
[14] Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab, 2020,42:101092.
[15] Mantovani A, Dalbeni A, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of macro- and microvascular complications in patients with type 2 diabetes. J Clin Med, 2022,11(4):968.
[16] Riaz A, Asghar S, Shahid S,et al. Prevalence of metabolic syndrome and its risk factors influence on microvascular complications in patients with type 1 and type 2 diabetes mellitus. Cureus, 2024,16(3):e55478.
[17] Heo YJ, Choi SE, Jeon JY,et al. Visfatin induces inflammation and insulin resistance via the NF-κB and STAT3 signaling pathways in hepatocytes. J Diabetes Res, 2019,2019:4021623.
[18] Marjani S, Nezhadali M, Hekmat A,et al. Investigating visfatin gene polymorphism rs4730153 with insulin resistance and non-alcoholic fatty liver diseases in iranian population. Iran J Public Health, 2022,51(5):1143-1151.
[19] Francisco V, Sanz MJ, Real JT,et al. Adipokines in non-alcoholic fatty liver disease: are we on the road toward new biomarkers and therapeutic targets? Biology (Basel), 2022,11(8):1237.
[20] Assem M, Amin M, Khalafallah O, et al. Hypoadiponectinemia as a marker of increased cardiovascular risk in patients with non-alcoholic fatty liver disease: correlation with albumin/creatinine ratio. Arch Endocrinol Metab, 2021,65(1):93-97.
[21] Han E, Kim MK, Jang BK,et al. Albuminuria is associated with steatosis burden in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Diabetes Metab J, 2021,45(5):698-707.

Serum visfatin, body composition and ACR changes in patients with type 2 diabetes mellitus and concomitant nonalcoholic fatty liver disease and their relationship with the occurrence of macrovascular complications

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Li Xiaoqing, Liu Yingjian, Cao Hui, et al. Prediction of concomitant nonalcoholic fatty liver disease in patients with type two diabetes mellitus by visceral fat area and blood lipid [J]. Journal of Practical Hepatology, 2026, 29(1): 49-52.
[2]	Shi Lingyun, Wu Binbin, Shi Yanli. Implication of serum RBP-4, FGF21 and NF-κB levels in patients with NAFLD and concomitant T2DM [J]. Journal of Practical Hepatology, 2026, 29(1): 53-56.
[3]	Li Hui, Tao Ya, Xu Xunmei, et al. Efficacy of liraglutide in the treatment of patients with NAFLD and T2DM and its impact on peripheral blood mononuclear cell NLRP3, Caspase-1 and ASC levels [J]. Journal of Practical Hepatology, 2025, 28(6): 830-833.
[4]	Wang Meiling, Li Jie, Liu Juan, et al. Semaglutide in combination with fenofibrate in the treatment of patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(6): 838-841.
[5]	Gao Hai’na, Liang Pan, Gao Linhui, et al. Combination of exenatide and metformin in treatment of patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: A pilot study [J]. Journal of Practical Hepatology, 2025, 28(6): 842-845.
[6]	Chen Xiaoling, Zhang Panpan, Fu Yufang, et al. Clinical efficacy of semaglutidein combination with Huatan Quyu Tongluo decoction in the treatment of patients with NAFLD and T2DM: A pilot study [J]. Journal of Practical Hepatology, 2025, 28(6): 846-849.
[7]	Chen Ruiting, Yuan Kemin, Peng Xiaolong. Changes of serum sex hormones and thyroid hormones in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(5): 691-694.
[8]	Cheng Zhonghua, Tang Nan, Gu Shuo, et al. Serum miR-122, miR-140-5p and miR-34a levels in patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(5): 695-698.
[9]	Zhang Lei, Wang Yaru, Li Huiping, et al. Clinical observation of semaglutide and metformin combination in treatment of patients with type 2 diabetes mellitus and concomitant nonalcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2025, 28(5): 699-702.
[10]	Ge Tianming, Wu Qiyuan, Yu Xiaowei, et al. Verification of magnetic resonance imaging proton density fat fraction in predicting liver steatosis in patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(5): 703-706.
[11]	Shi Dandan, Ai Bichen, Ma Qixin, et al. Foles of bile acid FXR receptor on glycolipid metabolism in non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(4): 489-492.
[12]	Zhang Shuwei, Zhang Huijuan, Zhou Jie. Clinical observation of rosiglitazone and metformin combination in the treatment of patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2025, 28(4): 545-548.
[13]	Yang Hao, Yi Bo, Liu Hongyan. Clinical implications of serum IFN-α and IFN-β levels in patients with T2DM and metabolic-associated fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(4): 557-560.
[14]	Chen Chunru, Qi Haolong, Lu Cong, et al. Impact of circadian rhythms on pathogenesis of non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(3): 321-325.
[15]	Xu Lingling, Lu Yuan, Zheng Yanchai, et al. Improvement of liver function tests by oral bicyclol in patients with type 2 diabetes mellitus and nonalcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2025, 28(3): 358-361.